RLYB (Rallybio) Net Margin % : -3,834.78% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rallybio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Rallybio's Net Income for the three months ended in Sep. 2024 was $-11.47 Mil. Rallybio's Revenue for the three months ended in Sep. 2024 was $0.30 Mil. Therefore, Rallybio's net margin for the quarter that ended in Sep. 2024 was -3,834.78%.

The historical rank and industry rank for Rallybio's Net Margin % or its related term are showing as below:

RLYB' s Net Margin % Range Over the Past 10 Years
Min: -9084.12 Med: 0 Max: 0
Current: -9084.12

RLYB's Net Margin % is ranked worse than
92.93% of 1004 companies
in the Biotechnology industry
Industry Median: -135.865 vs RLYB: -9084.12

Rallybio Net Margin % Historical Data

The historical data trend for Rallybio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rallybio Net Margin % Chart

Rallybio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Margin %

Get a 7-Day Free Trial

-9,084.12

Rallybio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial															-	-	-5,430.10	-3,834.78	-29,063.16

Competitive Comparison of Rallybio's Net Margin %

For the Biotechnology subindustry, Rallybio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rallybio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rallybio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Rallybio's Net Margin % falls into.

Rallybio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Rallybio's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-74.564	/	0
	=	%

Rallybio's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin	=	Net Income (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-11.466	/	0.299
	=	-3,834.78 %

Rallybio (NAS:RLYB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Rallybio Net Margin % Related Terms

Thank you for viewing the detailed overview of Rallybio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rallybio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rallybio Corp (NAS:RLYB) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

234 Church Street, Suite 1020, New Haven, CT, USA, 06510

Website

https://www.rallybio.com

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Executives

5am Partners V, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jonathan I Lieber	officer: See Remarks	C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Wendy Chung	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Hui Liu	director	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Christine A Nash	director	C/O RALLYBIO CORPORATION, 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510